A discovery by Queensland scientists could be the key to stopping damage caused by uncontrolled inflammation in a range of common diseases including liver disease, Alzheimer’s and gout.
University of Queensland researchers have uncovered how an inflammation process automatically switches off in healthy cells, and are now investigating ways to stop it manually when it goes awry.
“Now that we understand how this pathway naturally turns off in health, we can investigate why it doesn’t turn off in disease — so it’s very exciting,” Dr Schroder said.
Her work at IMB’s Centre for Inflammation and Disease Research focuses on inflammasomes, which are machine-like protein complexes at the heart of inflammation and disease.
“These complexes form when an infection, injury or other disturbance is detected by the immune system, and they send messages to immune cells to tell them to respond,” Dr Schroder said.
“If the disturbance can’t be cleared, such as in the case of amyloid plaques in Alzheimer’s, these molecular machines continue to fire, resulting in neurodegenerative damage from the sustained inflammation.”
Dr Schroder’s team, led by Dr Dave Boucher, discovered that inflammasomes normally work with an in-built timer switch, to ensure they only fire for a specific length of time once triggered.
“The inflammasome initiates the inflammation process by activating a protein that functions like a pair of scissors, and cuts itself and other proteins,” Dr Schroder said.
“What we’ve found is that after a period of time this protein cuts itself a second time to turn off the pathway, so if we can tweak this system we may be able to turn it off manually in disease.”
Dr Schroder’s laboratory has begun studying the inflammasome in fatty liver disease, a rapidly growing health issue due to the increasing global incidence of obesity and diabetes.
“In some patients with this condition the liver becomes increasingly fatty and inflamed, and this can lead to cirrhosis – which can require liver transplantation – or even liver cancer.”
Compounds to block inflammasome have been developed by IMB researchers including Dr Schroder, and are being commercialised by start-up drug development company Inflazome Ltd.
The research, published in the Journal of Experimental Medicine (DOI: 10.1084/jem.20172222), was supported by the Australian Research Council, and involved laboratories at IMB and the UQ School of Chemistry and Molecular Biosciences.
Imaging for the project was performed in the IMB Cancer Biology Imaging Facility, funded by the Australian Cancer Research Foundation.
Additional video: inflammasome animation on YouTube.
The Latest on: Uncontrolled inflammation
via Google News
The Latest on: Uncontrolled inflammation
- Dietary interventions to optimize healing of injury-induced inflammationon August 10, 2020 at 2:50 pm
Injuries induce the initiation of inflammation to control the damage. However, the resolution of the injury-induced inflammation leading to healing is not well characterized.
- More children stricken with COVID-19 inflammatory reaction, 29 in Californiaon August 7, 2020 at 10:45 pm
Researchers found a growing number of children in California and other states with severe COVID-19 symptoms, including multi-system inflammatory syndrome, or MIS-C, which causes abdominal pain, ...
- Coronavirus News: 8-year-old boy who survived mystery illness linked to COVID-19 honored by hospitalon August 7, 2020 at 6:05 pm
An 8-year-old boy from Westchester County who nearly died from Multi-System Inflammatory Syndrome, an illness seen in pediatric patients linked to the COVID-19 infection, was honored Thursday by the ...
- At least 3 cases of inflammatory illness linked to COVID-19 treated at Dell Children’son August 7, 2020 at 2:03 pm
Dell Children’s Medical Center says it has treated three confirmed cases of an inflammatory illness linked to COVID-19 that especially afflicts children.
- Researchers Use Supercomputers To Discover New Pathway For Covid-19 Inflammationon August 5, 2020 at 5:19 pm
Research shows that there can be six distinct "types" of the disease involving different clusters of symptoms.
- BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatmenton August 5, 2020 at 3:16 pm
BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, ...
- The yin and yang of inflammation controlled by a single moleculeon August 5, 2020 at 8:02 am
Researchers from the Perelman School of Medicine at the University of Pennsylvania have now identified a protein called histone deacetylase 3 (HDAC3) as the orchestrator of the immune system's ...
- The BXD21/TyJ recombinant inbred strain as a model for innate inflammatory response in distinct brain regionson August 5, 2020 at 2:10 am
As independent variables STRAIN (BXD84/RwwJ RI, BXD21/TyJ RI and control mice (C57BL/6) and SEX (female and male) were used. Post hoc analysis was performed with Bonferroni test. At 7-months-of-age, ...
- CDC study: 73% of kids with coronavirus-related inflammatory condition were previously healthyon August 3, 2020 at 10:48 pm
A recent study funded by the Centers for Disease Control and Prevention (CDC) reaffirmed reports of an emerging, life-threatening inflammatory syndrome among some youth in the US, thought to be ...
via Bing News